JOJamie Marie Orengo

Jamie Marie Orengo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jamie Marie Orengo has a total of 432 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Maftivimab monotherapy is effective in a non-human primate model of Bundibugyo virus disease

    by Meike Dittmann, Dylan M. Johnson, Micah Rapp, Alida Coppi, Flonza Isa, Dharani Ajithdoss, Anbo Zhou, Benjamin O. Fulton, Ranu Basu, Anna K. Kania, et al.

    The 2026 outbreak of Bundibugyo ebolavirus (BDBV) in the Democratic Republic of the Congo and Uganda has created an urgent need for treatments for BDBV disease, yet the only FDA-approved ebolavirus therapeutics, the monoclonal antibody (mAb) cocktail Inmazeb® and the mAb Ebanga®, are indicated for Zaire ebolavirus (EBOV). Maftivimab (REGN3479), the most potent neutralizing component of Inmazeb®, targets ebolavirus species GPs broadly; however, how it engages BDBV GP, whether it neutralizes BDBV-2026, and whether it protects against BDBV disease in vivo are unknown. Here we show that Maftivimab binds to BDBV-2007 GP with high affinity and potently neutralizes pseudoviruses carrying GP from a 2007 reference strain and the 2026 outbreak lineage. Additionally, a cryo-electron microscopy structure of Maftivimab Fab bound to trimeric BDBV-2007 GP superimposes closely on the EBOV GP–Maftivimab complex; importantly, all GP contact residues are conserved between the 2007 and 2026 BDBV sequences. Finally, in cynomolgus macaques challenged with BDBV-2007, a single dose of Maftivimab monotherapy given 7 days after infection, after the onset of clinical disease, rescued 6 of 6 animals, whereas 5 of 6 placebo-treated animals succumbed. These findings demonstrate that Maftivimab neutralizes BDBV, binds to its epitope on BDBV GP and is efficacious in treating established BDBV disease in the macaque model. The data support its evaluation in clinical trials during the ongoing or future outbreak.


  • Open Access

    Dysregulated tissue immunity in human fatal asthma

    by Yoonseung A. Lee, Steven B. Wells, Daniel C. Yee, Daniel P. Caron, Nora Lam, Derek A. Martinez, Rei Matsumoto, Yosuke Sakamoto, Andrea Vecchione, Amanda Atanasio, et al.

    Asthma is an immune-mediated lung disease causing airway constriction that is fatal in rare cases, though the immune mechanisms underlying asthma severity are poorly understood. Here, we present a comprehensive immunological profiling of lymphoid organs, lungs, and intestines from human organ donors who died of fatal asthma (FA) compared to donors who died of unrelated causes with or without a history of asthma. Compared to control donors, FA donors exhibit elevated plasma IgE along with enhanced and aberrant immune responses in mucosal-associated lymph nodes (LN) and lungs, respectively. In particular, FA donors show increased memory T and B cells and decreased Treg cells with age in the gut- and lung-associated LN, increased Th2 and Th1 resident memory cells in the lungs, and increased associations between gut and lung immune responses compared to control donors. Our findings reveal mucosal immune dysregulation underlying asthma exacerbation through site-specific and inter-tissue disruption of immune homeostasis.

  • Open Access

    Autoimmune hepatitis and primary biliary cholangitis are among a subset of autoimmune diseases defined by profound co-prevalence and genetic risk association with the IL12 pathway

    by Priyanka Nakka, Brian D. Hobbs, Carlo Sidore, William H. Palmer, Dana Murdock, Lauren Gurski, Arielle Glatman Zaretsky, Keran Moll, Adrian I. Campos, Amit Joshi, et al.

    Background and Aims: Distinct autoimmune diseases can share symptoms and autoantibodies, but the molecular pathways underlying this shared etiology remain poorly understood. We assessed genetic support for IL12 signaling across 27 diseases. Approach and Results: We identified a rare variant upstream of IL12A with large risk-increasing effects on autoimmune hepatitis [AIH; per-allele odds ratio (OR)=2.98, p =3×10 −9 ], primary biliary cholangitis (PBC; OR=2.80, p =2×10 −8 ), systemic sclerosis (SSc; OR=2.64, p =2×10 −11 ), Sjogren's disease (SjD; OR=1.94, p =10 −11 ), systemic lupus erythematosus (SLE; OR=1.83, p =5×10 −10 ) and multiple sclerosis (OR=1.79, p =10 −11 ). Lifetime risk for developing at least one of these conditions increased 6-fold in homozygote carriers (OR=5.73, p =0.003). We then evaluated genetic support for all 4 IL12 signaling genes and found that: (i) a non-coding variant downstream of IL12A (linked to lower gene expression) protected against 5 of the 6 diseases; (ii) an intronic variant in IL12RB2 (linked to higher gene expression) increased risk of all 6 diseases; and (iii) heterozygote carriers of rare predicted loss-of-function or missense variants in IL12RB2 had 18% lower odds of SLE (OR=0.82, p =2×10 −5 ). IL23 signaling, which shares ligand and receptor subunits with IL12, was not associated with these conditions. In epidemiologic analyses of co-prevalence, 5 of the 6 diseases strongly co-occurred with each other: AIH, PBC, SSc, SjD and SLE. Conclusions: AIH, PBC, SSc, SjD and SLE represent a distinct subset of autoimmune diseases that share genetic associations with the IL12 pathway, as well as profound co-prevalence, suggesting they may have a shared etiology and may respond to the same targeted therapeutic intervention(s).


  • Open Access

    Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

    by Jennifer D. Hamilton, Manuel A. R. Ferreira, Wei Keat Lim, Carlo Sidore, Matthew F. Wipperman, Wenzhen Ge, Xue Song, Changming Xia, Julie E. Horowitz, Andrea T. Hooper, et al.

    Background: It has long been appreciated that multiple allergic/atopic conditions (type‐2‐inflammation‐associated diseases, T2IDs) often appear in the same individual, suggesting a shared systemic immune deviation. Emerging molecular and clinical investigations of interleukin (IL)4/IL13 blockade with the fully‐human antibody dupilumab suggest that many are driven by over‐activation of the IL4/IL13 pathway, manifesting differently in distinct tissues. Methods and Results: We performed comprehensive quantitative analyses using several large, independent datasets (including real‐world and clinical trial datasets) to confirm that many T2IDs—including asthma, atopic dermatitis, eosinophilic esophagitis, nasal polyps, prurigo nodularis—are highly interrelated based on co‐prevalence, genetic predispositions, and transcriptomic signatures driven by over‐activation of the IL4/IL13 pathway. We also summarize extensive clinical trial data showing that these T2IDs also share uniformly impressive clinical responses to dual IL4/IL13 blockade with dupilumab. Conclusions: While highly consistent with previous data and observations, this is the first systematic comparison of these types of data across multiple T2IDs, using a rigorous quantitative assessment of the largest datasets evaluated to date. Many T2IDs are not only highly interrelated and comorbid, but share transcriptomic signatures and genetic predispositions that suggest they all share over‐activation of the IL4/IL13 pathway as a key causative driver, consistent with and explaining their uniform clinical responsiveness to dual IL4/IL13 blockade. These genetic and transcriptomic signatures may also have utility for identifying other diseases mediated by IL4/IL13 or T2‐mediated subpopulations of heterogenous inflammatory diseases.


  • Open Access

    IL-33 expands plasma cells, disrupts germinal centers, and increases autoantibody production in mice

    by Eva Conde, Seblewongel Asrat, Andrea Vecchione, Kaitlyn Gayvert, Paulina Pedraza, Carley Tasker, Sharon Huang, Dmitry Yarilin, Dylan Birchard, Li-Hong Ben, et al.

    IL-33 is an inflammatory cytokine contributing to asthma, Chronic Obstructive Pulmonary Disease (COPD), and autoimmune diseases. Although recent studies suggest that IL-33 can induce the generation of autoantibodies, the role of IL-33 on B cell maturation and tolerance is poorly understood. Here, by inducing systemic overexpression of IL-33 in mice, we show that this cytokine induces the IL-5 and CD4 T cell-dependent accumulation of plasmablasts and plasma cells of all isotypes in the spleen, and leads to an increased antibody production. IL-33 also disrupts splenic architecture and elevates autoantibody production, indicating a break in peripheral tolerance. Consistently, elevated levels of IL-33 exacerbate autoantibody production, kidney damage, and decrease survival in a mouse model of lupus. Additionally, intranasal delivery of IL-33 in mice exposed to house dust mite extract (HDM) increases autoantibodies in the lung. Notably, blocking IL-33 reduced the autoantibodies generated during HDM exposure, indicating that HDM-induced autoantibody production is IL-33 dependent. Thus, our findings implicate IL-33 in the break of peripheral B cell tolerance, opening new therapeutic avenues for the treatment of infection, COPD and autoimmune conditions.


  • The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma

    by Seblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, Sivan Harel, Kaitlyn Gayvert, Dylan Birchard, Matthew F. Wipperman, Dave Singh, Andrea T. Hooper, George Scott, et al.

    Biologics targeting interleukin-4 receptor subunit α (IL-4Rα) and interleukin-33 (IL-33) have demonstrated clinical efficacy in asthma, highlighting the importance of IL-4, IL-13, and IL-33 in respiratory diseases. Despite this, few studies have linked preclinical models to human diseases or evaluated disease biology in clinical trials. To address these gaps, we evaluated transcriptional, cellular, and pathophysiological processes driven by IL-4/IL-13 and IL-33 using human innate cells in vitro, a mouse model of airway inflammation, and a bronchial allergen challenge (BAC) in house dust mite (HDM)–sensitized individuals with mild asthma. Our findings in mice revealed that the prophylactic blockade of IL-4/IL-13, but not IL-33, prevented the initiation of HDM-induced type 2 inflammation, whereas blocking IL-4Rα or IL-33 during peak inflammation ameliorated airway inflammation and remodeling. Each pathway had unique and overlapping effects on airway inflammation and remodeling, with combination blockade showing no additional benefit. Initiating either monotherapy during severe, mixed inflammation resulted in partial efficacy, whereas a combination of these two treatments led to a substantial reduction in airway inflammation and remodeling in sensitized mice. Some of these mechanistic observations translated to a human BAC model, where blocking IL-4Rα or IL-33 alone suppressed gene expression in sputum and circulating biomarkers. As observed in mice, combination treatment in individuals with allergic asthma did not provide additional benefit compared to monotherapy. Overall, these results provide insight into the differences in targeting IL-4Rα or IL-33 pathways in asthma independently or in combination.


  • Anatomical Distribution and Quantification of IgE Secretion in Mouse Models of House Dust Mite Allergy

    by Paul Haase, Angga Perima, Venkat Raman Ramnarayan, Patrick England, Bruno Iannascoli, Andre Limnander, Seblewongel Asrat, Andrea Vecchione, Jamie M. Orengo, Matthew A. Sleeman, et al.


  • Top Cited Papers
    Open Access

    Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy

    by R. Sharon Chinthrajah, Sayantani B. Sindher, Kari C. Nadeau, Jeffrey G. Leflein, Jonathan M. Spergel, Daniel H. Petroni, Stacie M. Jones, Thomas B. Casale, Julie Wang, Warner W. Carr, et al.

    Background: Peanut allergy is a common, life‐threatening food allergy in children. We evaluated whether dupilumab, which blocks the activity of interleukin (IL)‐4/IL‐13, enhances the efficacy of oral immunotherapy (OIT) AR101 in pediatric patients with peanut allergy. Methods: A Phase II, multicenter, randomized, double‐blind study was conducted in the USA (NCT03682770) in pediatric patients (6–≤ 17 years old) with confirmed peanut allergy. Patients were randomized 2:1 to receive dupilumab + OIT or placebo + OIT during a 28–40‐week up‐dosing period. Patients in the dupilumab + OIT group were re‐randomized 1:1 and received dupilumab + OIT or placebo + OIT during 24‐week OIT maintenance, undergoing a 2044 mg (cumulative) of peanut protein double‐blind, placebo‐controlled food challenge (DBPCFC) following up‐dosing, maintenance, and at 12‐week post‐treatment follow‐up. Results: The study enrolled 148 patients, 123 of whom were included in the modified full analysis set, with a mean age of 11.1 years. Dupilumab + OIT treatment ( n = 84) led to a 20.2% increase ( p < 0.05) in the number of patients who passed a DBPCFC to 2044 mg (cumulative) of peanut protein following the up‐dosing period versus placebo (OIT alone, n = 39). Following the OIT maintenance period, continuous dupilumab treatment improved the number of patients who passed a DBPCFC to 2044 mg (cumulative) of peanut protein versus patients continuously on OIT alone (16.6% difference [95% CI −9.7, 42.8], p = 0.2123). Safety was consistent with known dupilumab safety profile. Conclusions: Dupilumab provided a modest increase efficacy of OIT in children and adolescents with peanut allergy, though it did not provide protection against OIT‐related anaphylaxis. Trial Registration: ClinicalTrials.gov identifier: NCT03793608


  • Top Cited Papers
    Open Access

    Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase II Study

    by Sayantani B. Sindher, Kari C. Nadeau, R. Sharon Chinthrajah, Jeffrey G. Leflein, Philippe Bégin, Jason A. Ohayon, Punita Ponda, Erik Wambre, Jinzhong Liu, Faisal A. Khokhar, et al.

    Background: Peanut allergy is a potentially life‐threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)‐4/IL‐13, improved safety and desensitization to peanut exposure in children with peanut allergy.Methods: A Phase II, 24‐week, multicenter, single‐arm, open‐label, proof‐of‐concept study was conducted in the USA and Canada (NCT03793608). Children/adolescents with peanut allergy received subcutaneous dupilumab 300 mg (≥ 60 kg) or 200 mg (≥ 20 to < 60 kg) every 2 weeks. The primary endpoint was the proportion of participants who passed a double‐blind placebo‐controlled food challenge (DBPCFC) with ≥ 444 mg (cumulative) of peanut protein at week 24. Secondary endpoints included safety measures (Consortium of Food Allergy Research grading system) and change from baseline in peanut‐specific (ps)‐IgG4, total IgE, and ps‐IgE.Results: Twenty‐four participants enrolled and received dupilumab: 75.0% were male, 79.2% were white, mean (standard deviation) age was 11.7 (3.3) years. Most (95.8%) participants had not received allergen immunotherapy. Two participants (8.3%) achieved the primary endpoint and passed the DBPCFC at week 24. Fifteen participants (62.5%) reported 66 treatment‐emergent adverse events, all being mild or in moderate intensity. At the week 24 DBPCFC, 8 participants (33.3%) had a grade 2 allergic reaction (no grade 3 or above); 10 (41.7%) used adrenaline as a rescue medication. Dupilumab treatment resulted in a median reduction of total and ps‐IgE of −54% and −49%, respectively, and a 0% change in ps‐IgG4.Conclusions: Dupilumab monotherapy treatment for 24 weeks did not improve desensitization to peanut exposure after food challenge.


  • Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection

    by Christopher D. Petro, Andrea T. Hooper, Avery Peace, Kusha Mohammadi, Will Eagan, Sayda M. Elbashir, Anthony DiPiazza, Daniel Makrinos, Kristen Pascal, Pooja Bandawane, et al.

    Increased use of antiviral monoclonal antibodies (mAbs) for treatment and prophylaxis necessitates better understanding of their impact on endogenous immunity to vaccines and viruses. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presented an opportunity to study immunity in individuals who received antiviral mAbs and were subsequently immunized with vaccines encoding the mAb-targeted viral spike antigen. Here, we describe the impact of administration of an antibody combination, casirivimab plus imdevimab (CAS+IMD), on immune responses to subsequent SARS-CoV-2 vaccination in humans, nonhuman primates, and mice. The presence of CAS+IMD at the time of vaccination led to a specific diminishment of vaccine-elicited pseudovirus neutralizing antibody titers without overall dampening of spike protein–directed immune responses, including antibody, B cell, and T cell responses. The impact on pseudovirus neutralizing titers extended to other therapeutic anti–spike protein antibodies when used as either monotherapy or combination therapy. The specific reduction in pseudovirus neutralizing titers was the result of epitope masking, a phenomenon where specific epitopes are bound by high-affinity antibodies and blocked from B cell recognition. Encouragingly, this reduction in pseudovirus neutralizing titers was reversible with additional booster vaccination. Moreover, by assessing the antiviral immune response in SARS-CoV-2–infected individuals treated therapeutically with CAS+IMD, we demonstrated alteration of antiviral humoral immunity in those who had received mAb therapy, but only in those individuals who had yet to start mounting their natural immune response at the time of mAb treatment. Together, these data demonstrate that antiviral mAbs can alter endogenous humoral immunity during vaccination or infection.